Serum Cytokines and Bone Metabolic Markers in Patients with Rheumatoid Arthritis Treated with Biological Disease Modifying Anti-rheumatic Drugs

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2022 Sep 27

PMID 36163441

Authors

Hiroya Tamai

Naoshi Nishina

Jun Kikuchi

Keisuke Izumi

Kotaro Otomo

Keiko Yoshimoto

Kunihiro Yamaoka

Tsutomu Takeuchi

Yuko Kaneko

Affiliations

Soon will be listed here.

Abstract

Introduction: /objectives Several biological disease-modifying anti-rheumatic drugs (bDMARDs) have been widely used for the management of rheumatoid arthritis (RA). These drugs target different molecules important for the pathophysiology of RA; however, only a few studies have compared the effects of these biological drugs on cytokines and bone metabolic markers. The main aim of this study is to clarify the effects of bDMARDs with different modes of action on the cytokine and bone metabolic marker levels in patients with RA.

Methods: Patients with RA who were initiated on infliximab, tocilizumab, or abatacept as the first bDMARD were prospectively enrolled in this study. Serum cytokine and bone metabolic marker levels were measured longitudinally, and changes in their levels were compared.

Results: A total of 174 patients were enrolled in this study, with 55, 70, and 49 patients in the infliximab, tocilizumab, and abatacept groups, respectively. At six months, despite the similar clinical effectiveness of the three drugs, changes in the cytokine and bone metabolic marker levels were distinct; interferon-γ and tumor necrosis factor-α levels were significantly increased with infliximab, interleukin-6 levels were increased with tocilizumab, and interleukin-1β and interleukin-8 levels were increased with abatacept treatment. Bone-specific alkaline phosphatase and osteocalcin levels increased more significantly with tocilizumab than with infliximab, while osteopontin and osteonectin levels decreased with infliximab treatment.

Conclusions: bDMARDs with different modes of action exert different effects on the cytokine and bone metabolic marker levels in patients with RA.

Citing Articles

Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.

Martiniakova M, Biro R, Kovacova V, Babikova M, Zemanova N, Mondockova V J Mol Med (Berl). 2024; 102(4):435-452.

PMID: 38363329 PMC: 10963459. DOI: 10.1007/s00109-024-02418-8.

Sex differences in the effects of repeated ketamine infusions on bone markers in patients with unipolar and bipolar depression.

Lan X, Liu H, Wang C, Li W, Zhang F, Hu Z Biol Sex Differ. 2024; 15(1):12.

PMID: 38287453 PMC: 10826032. DOI: 10.1186/s13293-024-00587-2.

References

Odegard S, Landewe R, van der Heijde D, Kvien T, Mowinckel P, Uhlig T . Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum. 2005; 54(1):68-75. DOI: 10.1002/art.21548. View

Schett G, Elewaut D, McInnes I, Dayer J, Neurath M . How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med. 2013; 19(7):822-4. DOI: 10.1038/nm.3260. View

Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22):1594-602. DOI: 10.1056/NEJM200011303432202. View

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T . Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007; 66(9):1162-7. PMC: 1955155. DOI: 10.1136/ard.2006.068064. View

Kremer J, Genant H, Moreland L, Russell A, Emery P, Abud-Mendoza C . Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006; 144(12):865-76. DOI: 10.7326/0003-4819-144-12-200606200-00003. View

Walsh N, Reinwald S, Manning C, Condon K, Iwata K, Burr D . Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009; 24(9):1572-85. DOI: 10.1359/jbmr.090320. View

Lam J, Takeshita S, Barker J, Kanagawa O, Ross F, Teitelbaum S . TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000; 106(12):1481-8. PMC: 387259. DOI: 10.1172/JCI11176. View

Palmqvist P, Persson E, Conaway H, Lerner U . IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002; 169(6):3353-62. DOI: 10.4049/jimmunol.169.6.3353. View

Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J . CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008; 67(11):1603-9. DOI: 10.1136/ard.2007.080713. View

10.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky M, Dwyer D . Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13(2):156-63. DOI: 10.1038/nm1538. View

11.

Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M . IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab. 2013; 32(4):378-92. DOI: 10.1007/s00774-013-0514-1. View

12.

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

13.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

14.

van der Heijde D . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999; 26(3):743-5. View

15.

Takeshita M, Suzuki K, Kikuchi J, Izumi K, Kurasawa T, Yoshimoto K . Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. Cytokine. 2015; 75(2):222-7. DOI: 10.1016/j.cyto.2015.04.011. View

16.

Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U . P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature. 1997; 385(6611):81-3. DOI: 10.1038/385081a0. View

17.

Tak P, Taylor P, Breedveld F, Smeets T, Daha M, Kluin P . Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39(7):1077-81. DOI: 10.1002/art.1780390702. View

18.

Aeberli D, Seitz M, Juni P, Villiger P . Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2004; 44(2):172-5. DOI: 10.1093/rheumatology/keh437. View

19.

Charles P, Elliott M, Davis D, Potter A, Kalden J, Antoni C . Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999; 163(3):1521-8. View

20.

Brennan F, McInnes I . Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008; 118(11):3537-45. PMC: 2575731. DOI: 10.1172/JCI36389. View